Back to Newsroom

Seattle BioMed’s Researchers Develop Vaccine Candidate Using Genetically Engineered Malaria Parasite

Study published in Molecular Therapy provides path forward for highly protective malaria vaccine

Seattle, WA., May 29, 2014 — Seattle BioMed researchers today announced they have developed a next generation genetically attenuated parasite (GAP) that might constitute the path to a highly protective malaria vaccine. The study was published online in the journal Molecular Therapy.

Click here to read more